Global Conjugate Vaccines

Conjugate Vaccines Comprehensive Study by Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccines), Patient Stage (Pediatrics Conjugate Vaccine, Adults Conjugate Vaccine), Pathogen (Bacterial Conjugate Vaccine, Viral Conjugate Vaccine, Combination (Viral and Bacterial) Conjugate Vaccine), Disease Indication (Pneumococcal, Influenza, DTP, Meningococcal, Others) Players and Region - Global Market Outlook to 2030

Conjugate Vaccines Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Conjugate Vaccines
Conjugate Vaccine is a substance composed of conjugated to a carrier molecule. This improves the stability and effectiveness of the vaccine. Conjugate vaccines are targeting several leading causes of vaccine-preventable deaths. With the increasing number of death rates because of pneumococcal diseases, rotavirus, measles, Hib, and others. Most of the vaccines are manufactured with enhancing elicit immunological memory and reduce asymptomatic carriage of the bacteria.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


There are various companies that are exploring the footprint in new geographical regions by adopting various market growth strategies including mergers & acquisitions, expansions, investments, new solution launches, and others. The market key players are capturing market growth opportunities by rapidly investing in research and development initiatives. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Conjugate Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bharat Biotech (India), Biological E (India), CSL Limited (Australia), GlaxoSmithKline, plc. (United States.), Merck and Company (United States), Neuron Biotech (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States), Sanofi Pasteur (France) and Serum Institute of India (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Pfizer (United States), Sanofi Pasteur (France) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Conjugate Vaccines market by Type (Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccines) and Region. On the basis of Type, Bacterial Conjugate Vaccine are dominating the market in the year 2023



On the basis of geography, the market of Conjugate Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Patient Stage, the sub-segment i.e. Pediatrics Conjugate Vaccine will boost the Conjugate Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Pathogen, the sub-segment i.e. Bacterial Conjugate Vaccine will boost the Conjugate Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease Indication, the sub-segment i.e. Pneumococcal will boost the Conjugate Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increase in Investment in Research and Development and High Growth in Market Competencies

Market Growth Drivers:
The Rise in Occurrence Pneumococcal Diseases and Cause Increasing Number of Death Rates Across the Globe, Growing Demand for Vaccines to Enhance Immune and Memory Response and The Rise in Requirement for the Long-Lasting Protection

Challenges:
High Cost Associated with Raw Materials and Huge Investment Required to Enter this Market

Restraints:
Lack of Supply Chain in Under Developed Regions

Opportunities:
Growing Requirement for the Meningococcal Vaccines and Pneumococcal Vaccines

Market Leaders and their expansionary development strategies
In August 2022, GSK plc announced it has completed the acquisition of Affinivax, Inc, a clinical-stage biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
In March 2020, Pfizer announced its top-line results from one of its Phase 3 studies that evaluate the safety and immunogenicity of its 20 valent pneumococcal conjugate vaccines in 18 years, old people. Through this initiative, the company is enhanced its market revenue.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Conjugate Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Monovalent Conjugate Vaccines
  • Multivalent Conjugate Vaccines
By Patient Stage
  • Pediatrics Conjugate Vaccine
  • Adults Conjugate Vaccine

By Pathogen
  • Bacterial Conjugate Vaccine
  • Viral Conjugate Vaccine
  • Combination (Viral and Bacterial) Conjugate Vaccine

By Disease Indication
  • Pneumococcal
  • Influenza
  • DTP
  • Meningococcal
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rise in Occurrence Pneumococcal Diseases and Cause Increasing Number of Death Rates Across the Globe
      • 3.2.2. Growing Demand for Vaccines to Enhance Immune and Memory Response
      • 3.2.3. The Rise in Requirement for the Long-Lasting Protection
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated with Raw Materials
      • 3.3.2. Huge Investment Required to Enter this Market
    • 3.4. Market Trends
      • 3.4.1. Increase in Investment in Research and Development
      • 3.4.2. High Growth in Market Competencies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Conjugate Vaccines, by Type, Patient Stage, Pathogen, Disease Indication and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Conjugate Vaccines (Value)
      • 5.2.1. Global Conjugate Vaccines by: Type (Value)
        • 5.2.1.1. Monovalent Conjugate Vaccines
        • 5.2.1.2. Multivalent Conjugate Vaccines
      • 5.2.2. Global Conjugate Vaccines by: Patient Stage (Value)
        • 5.2.2.1. Pediatrics Conjugate Vaccine
        • 5.2.2.2. Adults Conjugate Vaccine
      • 5.2.3. Global Conjugate Vaccines by: Pathogen (Value)
        • 5.2.3.1. Bacterial Conjugate Vaccine
        • 5.2.3.2. Viral Conjugate Vaccine
        • 5.2.3.3. Combination (Viral and Bacterial) Conjugate Vaccine
      • 5.2.4. Global Conjugate Vaccines by: Disease Indication (Value)
        • 5.2.4.1. Pneumococcal
        • 5.2.4.2. Influenza
        • 5.2.4.3. DTP
        • 5.2.4.4. Meningococcal
        • 5.2.4.5. Others
      • 5.2.5. Global Conjugate Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Conjugate Vaccines (Volume)
      • 5.3.1. Global Conjugate Vaccines by: Type (Volume)
        • 5.3.1.1. Monovalent Conjugate Vaccines
        • 5.3.1.2. Multivalent Conjugate Vaccines
      • 5.3.2. Global Conjugate Vaccines by: Patient Stage (Volume)
        • 5.3.2.1. Pediatrics Conjugate Vaccine
        • 5.3.2.2. Adults Conjugate Vaccine
      • 5.3.3. Global Conjugate Vaccines by: Pathogen (Volume)
        • 5.3.3.1. Bacterial Conjugate Vaccine
        • 5.3.3.2. Viral Conjugate Vaccine
        • 5.3.3.3. Combination (Viral and Bacterial) Conjugate Vaccine
      • 5.3.4. Global Conjugate Vaccines by: Disease Indication (Volume)
        • 5.3.4.1. Pneumococcal
        • 5.3.4.2. Influenza
        • 5.3.4.3. DTP
        • 5.3.4.4. Meningococcal
        • 5.3.4.5. Others
      • 5.3.5. Global Conjugate Vaccines Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Conjugate Vaccines (Price)
      • 5.4.1. Global Conjugate Vaccines by: Type (Price)
  • 6. Conjugate Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bharat Biotech (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biological E (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CSL Limited (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline, plc. (United States.)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Neuron Biotech (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi Pasteur (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Serum Institute of India (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Conjugate Vaccines Sale, by Type, Patient Stage, Pathogen, Disease Indication and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Conjugate Vaccines (Value)
      • 7.2.1. Global Conjugate Vaccines by: Type (Value)
        • 7.2.1.1. Monovalent Conjugate Vaccines
        • 7.2.1.2. Multivalent Conjugate Vaccines
      • 7.2.2. Global Conjugate Vaccines by: Patient Stage (Value)
        • 7.2.2.1. Pediatrics Conjugate Vaccine
        • 7.2.2.2. Adults Conjugate Vaccine
      • 7.2.3. Global Conjugate Vaccines by: Pathogen (Value)
        • 7.2.3.1. Bacterial Conjugate Vaccine
        • 7.2.3.2. Viral Conjugate Vaccine
        • 7.2.3.3. Combination (Viral and Bacterial) Conjugate Vaccine
      • 7.2.4. Global Conjugate Vaccines by: Disease Indication (Value)
        • 7.2.4.1. Pneumococcal
        • 7.2.4.2. Influenza
        • 7.2.4.3. DTP
        • 7.2.4.4. Meningococcal
        • 7.2.4.5. Others
      • 7.2.5. Global Conjugate Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Conjugate Vaccines (Volume)
      • 7.3.1. Global Conjugate Vaccines by: Type (Volume)
        • 7.3.1.1. Monovalent Conjugate Vaccines
        • 7.3.1.2. Multivalent Conjugate Vaccines
      • 7.3.2. Global Conjugate Vaccines by: Patient Stage (Volume)
        • 7.3.2.1. Pediatrics Conjugate Vaccine
        • 7.3.2.2. Adults Conjugate Vaccine
      • 7.3.3. Global Conjugate Vaccines by: Pathogen (Volume)
        • 7.3.3.1. Bacterial Conjugate Vaccine
        • 7.3.3.2. Viral Conjugate Vaccine
        • 7.3.3.3. Combination (Viral and Bacterial) Conjugate Vaccine
      • 7.3.4. Global Conjugate Vaccines by: Disease Indication (Volume)
        • 7.3.4.1. Pneumococcal
        • 7.3.4.2. Influenza
        • 7.3.4.3. DTP
        • 7.3.4.4. Meningococcal
        • 7.3.4.5. Others
      • 7.3.5. Global Conjugate Vaccines Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Conjugate Vaccines (Price)
      • 7.4.1. Global Conjugate Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Conjugate Vaccines: by Type(USD Million)
  • Table 2. Conjugate Vaccines Monovalent Conjugate Vaccines , by Region USD Million (2018-2023)
  • Table 3. Conjugate Vaccines Multivalent Conjugate Vaccines , by Region USD Million (2018-2023)
  • Table 4. Conjugate Vaccines: by Patient Stage(USD Million)
  • Table 5. Conjugate Vaccines Pediatrics Conjugate Vaccine , by Region USD Million (2018-2023)
  • Table 6. Conjugate Vaccines Adults Conjugate Vaccine , by Region USD Million (2018-2023)
  • Table 7. Conjugate Vaccines: by Pathogen(USD Million)
  • Table 8. Conjugate Vaccines Bacterial Conjugate Vaccine , by Region USD Million (2018-2023)
  • Table 9. Conjugate Vaccines Viral Conjugate Vaccine , by Region USD Million (2018-2023)
  • Table 10. Conjugate Vaccines Combination (Viral and Bacterial) Conjugate Vaccine , by Region USD Million (2018-2023)
  • Table 11. Conjugate Vaccines: by Disease Indication(USD Million)
  • Table 12. Conjugate Vaccines Pneumococcal , by Region USD Million (2018-2023)
  • Table 13. Conjugate Vaccines Influenza , by Region USD Million (2018-2023)
  • Table 14. Conjugate Vaccines DTP , by Region USD Million (2018-2023)
  • Table 15. Conjugate Vaccines Meningococcal , by Region USD Million (2018-2023)
  • Table 16. Conjugate Vaccines Others , by Region USD Million (2018-2023)
  • Table 17. South America Conjugate Vaccines, by Country USD Million (2018-2023)
  • Table 18. South America Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 19. South America Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 20. South America Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 21. South America Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 22. Brazil Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 23. Brazil Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 24. Brazil Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 25. Brazil Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 26. Argentina Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 27. Argentina Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 28. Argentina Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 29. Argentina Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 30. Rest of South America Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 32. Rest of South America Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 33. Rest of South America Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 34. Asia Pacific Conjugate Vaccines, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 37. Asia Pacific Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 38. Asia Pacific Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 39. China Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 40. China Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 41. China Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 42. China Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 43. Japan Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 44. Japan Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 45. Japan Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 46. Japan Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 47. India Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 48. India Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 49. India Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 50. India Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 51. South Korea Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 52. South Korea Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 53. South Korea Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 54. South Korea Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 55. Taiwan Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 56. Taiwan Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 57. Taiwan Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 58. Taiwan Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 59. Australia Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 60. Australia Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 61. Australia Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 62. Australia Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 67. Europe Conjugate Vaccines, by Country USD Million (2018-2023)
  • Table 68. Europe Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 69. Europe Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 70. Europe Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 71. Europe Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 72. Germany Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 73. Germany Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 74. Germany Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 75. Germany Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 76. France Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 77. France Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 78. France Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 79. France Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 80. Italy Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 81. Italy Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 82. Italy Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 83. Italy Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 84. United Kingdom Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 86. United Kingdom Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 87. United Kingdom Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 88. Netherlands Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 89. Netherlands Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 90. Netherlands Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 91. Netherlands Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 92. Rest of Europe Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 94. Rest of Europe Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 95. Rest of Europe Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 96. MEA Conjugate Vaccines, by Country USD Million (2018-2023)
  • Table 97. MEA Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 98. MEA Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 99. MEA Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 100. MEA Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 101. Middle East Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 102. Middle East Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 103. Middle East Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 104. Middle East Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 105. Africa Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 106. Africa Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 107. Africa Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 108. Africa Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 109. North America Conjugate Vaccines, by Country USD Million (2018-2023)
  • Table 110. North America Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 111. North America Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 112. North America Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 113. North America Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 114. United States Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 115. United States Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 116. United States Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 117. United States Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 118. Canada Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 119. Canada Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 120. Canada Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 121. Canada Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 122. Mexico Conjugate Vaccines, by Type USD Million (2018-2023)
  • Table 123. Mexico Conjugate Vaccines, by Patient Stage USD Million (2018-2023)
  • Table 124. Mexico Conjugate Vaccines, by Pathogen USD Million (2018-2023)
  • Table 125. Mexico Conjugate Vaccines, by Disease Indication USD Million (2018-2023)
  • Table 126. Conjugate Vaccines Sales: by Type(K Units)
  • Table 127. Conjugate Vaccines Sales Monovalent Conjugate Vaccines , by Region K Units (2018-2023)
  • Table 128. Conjugate Vaccines Sales Multivalent Conjugate Vaccines , by Region K Units (2018-2023)
  • Table 129. Conjugate Vaccines Sales: by Patient Stage(K Units)
  • Table 130. Conjugate Vaccines Sales Pediatrics Conjugate Vaccine , by Region K Units (2018-2023)
  • Table 131. Conjugate Vaccines Sales Adults Conjugate Vaccine , by Region K Units (2018-2023)
  • Table 132. Conjugate Vaccines Sales: by Pathogen(K Units)
  • Table 133. Conjugate Vaccines Sales Bacterial Conjugate Vaccine , by Region K Units (2018-2023)
  • Table 134. Conjugate Vaccines Sales Viral Conjugate Vaccine , by Region K Units (2018-2023)
  • Table 135. Conjugate Vaccines Sales Combination (Viral and Bacterial) Conjugate Vaccine , by Region K Units (2018-2023)
  • Table 136. Conjugate Vaccines Sales: by Disease Indication(K Units)
  • Table 137. Conjugate Vaccines Sales Pneumococcal , by Region K Units (2018-2023)
  • Table 138. Conjugate Vaccines Sales Influenza , by Region K Units (2018-2023)
  • Table 139. Conjugate Vaccines Sales DTP , by Region K Units (2018-2023)
  • Table 140. Conjugate Vaccines Sales Meningococcal , by Region K Units (2018-2023)
  • Table 141. Conjugate Vaccines Sales Others , by Region K Units (2018-2023)
  • Table 142. South America Conjugate Vaccines Sales, by Country K Units (2018-2023)
  • Table 143. South America Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 144. South America Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 145. South America Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 146. South America Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 147. Brazil Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 148. Brazil Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 149. Brazil Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 150. Brazil Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 151. Argentina Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 152. Argentina Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 153. Argentina Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 154. Argentina Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 155. Rest of South America Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 156. Rest of South America Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 157. Rest of South America Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 158. Rest of South America Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 159. Asia Pacific Conjugate Vaccines Sales, by Country K Units (2018-2023)
  • Table 160. Asia Pacific Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 161. Asia Pacific Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 162. Asia Pacific Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 163. Asia Pacific Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 164. China Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 165. China Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 166. China Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 167. China Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 168. Japan Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 169. Japan Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 170. Japan Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 171. Japan Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 172. India Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 173. India Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 174. India Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 175. India Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 176. South Korea Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 177. South Korea Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 178. South Korea Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 179. South Korea Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 180. Taiwan Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 181. Taiwan Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 182. Taiwan Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 183. Taiwan Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 184. Australia Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 185. Australia Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 186. Australia Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 187. Australia Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 188. Rest of Asia-Pacific Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 189. Rest of Asia-Pacific Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 190. Rest of Asia-Pacific Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 191. Rest of Asia-Pacific Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 192. Europe Conjugate Vaccines Sales, by Country K Units (2018-2023)
  • Table 193. Europe Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 194. Europe Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 195. Europe Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 196. Europe Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 197. Germany Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 198. Germany Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 199. Germany Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 200. Germany Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 201. France Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 202. France Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 203. France Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 204. France Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 205. Italy Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 206. Italy Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 207. Italy Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 208. Italy Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 209. United Kingdom Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 210. United Kingdom Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 211. United Kingdom Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 212. United Kingdom Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 213. Netherlands Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 214. Netherlands Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 215. Netherlands Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 216. Netherlands Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 217. Rest of Europe Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 218. Rest of Europe Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 219. Rest of Europe Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 220. Rest of Europe Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 221. MEA Conjugate Vaccines Sales, by Country K Units (2018-2023)
  • Table 222. MEA Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 223. MEA Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 224. MEA Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 225. MEA Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 226. Middle East Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 227. Middle East Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 228. Middle East Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 229. Middle East Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 230. Africa Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 231. Africa Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 232. Africa Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 233. Africa Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 234. North America Conjugate Vaccines Sales, by Country K Units (2018-2023)
  • Table 235. North America Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 236. North America Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 237. North America Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 238. North America Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 239. United States Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 240. United States Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 241. United States Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 242. United States Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 243. Canada Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 244. Canada Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 245. Canada Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 246. Canada Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 247. Mexico Conjugate Vaccines Sales, by Type K Units (2018-2023)
  • Table 248. Mexico Conjugate Vaccines Sales, by Patient Stage K Units (2018-2023)
  • Table 249. Mexico Conjugate Vaccines Sales, by Pathogen K Units (2018-2023)
  • Table 250. Mexico Conjugate Vaccines Sales, by Disease Indication K Units (2018-2023)
  • Table 251. Conjugate Vaccines: by Type(USD/Units)
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Conjugate Vaccines: by Type(USD Million)
  • Table 263. Conjugate Vaccines Monovalent Conjugate Vaccines , by Region USD Million (2025-2030)
  • Table 264. Conjugate Vaccines Multivalent Conjugate Vaccines , by Region USD Million (2025-2030)
  • Table 265. Conjugate Vaccines: by Patient Stage(USD Million)
  • Table 266. Conjugate Vaccines Pediatrics Conjugate Vaccine , by Region USD Million (2025-2030)
  • Table 267. Conjugate Vaccines Adults Conjugate Vaccine , by Region USD Million (2025-2030)
  • Table 268. Conjugate Vaccines: by Pathogen(USD Million)
  • Table 269. Conjugate Vaccines Bacterial Conjugate Vaccine , by Region USD Million (2025-2030)
  • Table 270. Conjugate Vaccines Viral Conjugate Vaccine , by Region USD Million (2025-2030)
  • Table 271. Conjugate Vaccines Combination (Viral and Bacterial) Conjugate Vaccine , by Region USD Million (2025-2030)
  • Table 272. Conjugate Vaccines: by Disease Indication(USD Million)
  • Table 273. Conjugate Vaccines Pneumococcal , by Region USD Million (2025-2030)
  • Table 274. Conjugate Vaccines Influenza , by Region USD Million (2025-2030)
  • Table 275. Conjugate Vaccines DTP , by Region USD Million (2025-2030)
  • Table 276. Conjugate Vaccines Meningococcal , by Region USD Million (2025-2030)
  • Table 277. Conjugate Vaccines Others , by Region USD Million (2025-2030)
  • Table 278. South America Conjugate Vaccines, by Country USD Million (2025-2030)
  • Table 279. South America Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 280. South America Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 281. South America Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 282. South America Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 283. Brazil Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 284. Brazil Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 285. Brazil Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 286. Brazil Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 287. Argentina Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 288. Argentina Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 289. Argentina Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 290. Argentina Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 291. Rest of South America Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 292. Rest of South America Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 293. Rest of South America Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 294. Rest of South America Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 295. Asia Pacific Conjugate Vaccines, by Country USD Million (2025-2030)
  • Table 296. Asia Pacific Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 297. Asia Pacific Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 298. Asia Pacific Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 299. Asia Pacific Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 300. China Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 301. China Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 302. China Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 303. China Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 304. Japan Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 305. Japan Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 306. Japan Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 307. Japan Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 308. India Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 309. India Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 310. India Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 311. India Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 312. South Korea Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 313. South Korea Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 314. South Korea Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 315. South Korea Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 316. Taiwan Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 317. Taiwan Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 318. Taiwan Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 319. Taiwan Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 320. Australia Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 321. Australia Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 322. Australia Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 323. Australia Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 324. Rest of Asia-Pacific Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 325. Rest of Asia-Pacific Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 326. Rest of Asia-Pacific Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 327. Rest of Asia-Pacific Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 328. Europe Conjugate Vaccines, by Country USD Million (2025-2030)
  • Table 329. Europe Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 330. Europe Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 331. Europe Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 332. Europe Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 333. Germany Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 334. Germany Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 335. Germany Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 336. Germany Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 337. France Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 338. France Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 339. France Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 340. France Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 341. Italy Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 342. Italy Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 343. Italy Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 344. Italy Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 345. United Kingdom Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 346. United Kingdom Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 347. United Kingdom Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 348. United Kingdom Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 349. Netherlands Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 350. Netherlands Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 351. Netherlands Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 352. Netherlands Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 353. Rest of Europe Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 354. Rest of Europe Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 355. Rest of Europe Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 356. Rest of Europe Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 357. MEA Conjugate Vaccines, by Country USD Million (2025-2030)
  • Table 358. MEA Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 359. MEA Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 360. MEA Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 361. MEA Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 362. Middle East Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 363. Middle East Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 364. Middle East Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 365. Middle East Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 366. Africa Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 367. Africa Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 368. Africa Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 369. Africa Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 370. North America Conjugate Vaccines, by Country USD Million (2025-2030)
  • Table 371. North America Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 372. North America Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 373. North America Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 374. North America Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 375. United States Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 376. United States Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 377. United States Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 378. United States Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 379. Canada Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 380. Canada Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 381. Canada Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 382. Canada Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 383. Mexico Conjugate Vaccines, by Type USD Million (2025-2030)
  • Table 384. Mexico Conjugate Vaccines, by Patient Stage USD Million (2025-2030)
  • Table 385. Mexico Conjugate Vaccines, by Pathogen USD Million (2025-2030)
  • Table 386. Mexico Conjugate Vaccines, by Disease Indication USD Million (2025-2030)
  • Table 387. Conjugate Vaccines Sales: by Type(K Units)
  • Table 388. Conjugate Vaccines Sales Monovalent Conjugate Vaccines , by Region K Units (2025-2030)
  • Table 389. Conjugate Vaccines Sales Multivalent Conjugate Vaccines , by Region K Units (2025-2030)
  • Table 390. Conjugate Vaccines Sales: by Patient Stage(K Units)
  • Table 391. Conjugate Vaccines Sales Pediatrics Conjugate Vaccine , by Region K Units (2025-2030)
  • Table 392. Conjugate Vaccines Sales Adults Conjugate Vaccine , by Region K Units (2025-2030)
  • Table 393. Conjugate Vaccines Sales: by Pathogen(K Units)
  • Table 394. Conjugate Vaccines Sales Bacterial Conjugate Vaccine , by Region K Units (2025-2030)
  • Table 395. Conjugate Vaccines Sales Viral Conjugate Vaccine , by Region K Units (2025-2030)
  • Table 396. Conjugate Vaccines Sales Combination (Viral and Bacterial) Conjugate Vaccine , by Region K Units (2025-2030)
  • Table 397. Conjugate Vaccines Sales: by Disease Indication(K Units)
  • Table 398. Conjugate Vaccines Sales Pneumococcal , by Region K Units (2025-2030)
  • Table 399. Conjugate Vaccines Sales Influenza , by Region K Units (2025-2030)
  • Table 400. Conjugate Vaccines Sales DTP , by Region K Units (2025-2030)
  • Table 401. Conjugate Vaccines Sales Meningococcal , by Region K Units (2025-2030)
  • Table 402. Conjugate Vaccines Sales Others , by Region K Units (2025-2030)
  • Table 403. South America Conjugate Vaccines Sales, by Country K Units (2025-2030)
  • Table 404. South America Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 405. South America Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 406. South America Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 407. South America Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 408. Brazil Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 409. Brazil Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 410. Brazil Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 411. Brazil Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 412. Argentina Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 413. Argentina Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 414. Argentina Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 415. Argentina Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 416. Rest of South America Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 417. Rest of South America Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 418. Rest of South America Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 419. Rest of South America Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 420. Asia Pacific Conjugate Vaccines Sales, by Country K Units (2025-2030)
  • Table 421. Asia Pacific Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 422. Asia Pacific Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 423. Asia Pacific Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 424. Asia Pacific Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 425. China Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 426. China Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 427. China Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 428. China Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 429. Japan Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 430. Japan Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 431. Japan Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 432. Japan Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 433. India Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 434. India Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 435. India Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 436. India Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 437. South Korea Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 438. South Korea Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 439. South Korea Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 440. South Korea Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 441. Taiwan Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 442. Taiwan Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 443. Taiwan Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 444. Taiwan Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 445. Australia Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 446. Australia Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 447. Australia Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 448. Australia Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 449. Rest of Asia-Pacific Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 450. Rest of Asia-Pacific Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 451. Rest of Asia-Pacific Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 452. Rest of Asia-Pacific Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 453. Europe Conjugate Vaccines Sales, by Country K Units (2025-2030)
  • Table 454. Europe Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 455. Europe Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 456. Europe Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 457. Europe Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 458. Germany Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 459. Germany Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 460. Germany Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 461. Germany Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 462. France Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 463. France Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 464. France Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 465. France Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 466. Italy Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 467. Italy Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 468. Italy Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 469. Italy Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 470. United Kingdom Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 471. United Kingdom Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 472. United Kingdom Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 473. United Kingdom Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 474. Netherlands Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 475. Netherlands Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 476. Netherlands Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 477. Netherlands Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 478. Rest of Europe Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 479. Rest of Europe Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 480. Rest of Europe Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 481. Rest of Europe Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 482. MEA Conjugate Vaccines Sales, by Country K Units (2025-2030)
  • Table 483. MEA Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 484. MEA Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 485. MEA Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 486. MEA Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 487. Middle East Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 488. Middle East Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 489. Middle East Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 490. Middle East Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 491. Africa Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 492. Africa Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 493. Africa Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 494. Africa Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 495. North America Conjugate Vaccines Sales, by Country K Units (2025-2030)
  • Table 496. North America Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 497. North America Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 498. North America Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 499. North America Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 500. United States Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 501. United States Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 502. United States Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 503. United States Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 504. Canada Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 505. Canada Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 506. Canada Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 507. Canada Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 508. Mexico Conjugate Vaccines Sales, by Type K Units (2025-2030)
  • Table 509. Mexico Conjugate Vaccines Sales, by Patient Stage K Units (2025-2030)
  • Table 510. Mexico Conjugate Vaccines Sales, by Pathogen K Units (2025-2030)
  • Table 511. Mexico Conjugate Vaccines Sales, by Disease Indication K Units (2025-2030)
  • Table 512. Conjugate Vaccines: by Type(USD/Units)
  • Table 513. Research Programs/Design for This Report
  • Table 514. Key Data Information from Secondary Sources
  • Table 515. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Conjugate Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Conjugate Vaccines: by Patient Stage USD Million (2018-2023)
  • Figure 6. Global Conjugate Vaccines: by Pathogen USD Million (2018-2023)
  • Figure 7. Global Conjugate Vaccines: by Disease Indication USD Million (2018-2023)
  • Figure 8. South America Conjugate Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Conjugate Vaccines Share (%), by Country
  • Figure 10. Europe Conjugate Vaccines Share (%), by Country
  • Figure 11. MEA Conjugate Vaccines Share (%), by Country
  • Figure 12. North America Conjugate Vaccines Share (%), by Country
  • Figure 13. Global Conjugate Vaccines: by Type K Units (2018-2023)
  • Figure 14. Global Conjugate Vaccines: by Patient Stage K Units (2018-2023)
  • Figure 15. Global Conjugate Vaccines: by Pathogen K Units (2018-2023)
  • Figure 16. Global Conjugate Vaccines: by Disease Indication K Units (2018-2023)
  • Figure 17. South America Conjugate Vaccines Share (%), by Country
  • Figure 18. Asia Pacific Conjugate Vaccines Share (%), by Country
  • Figure 19. Europe Conjugate Vaccines Share (%), by Country
  • Figure 20. MEA Conjugate Vaccines Share (%), by Country
  • Figure 21. North America Conjugate Vaccines Share (%), by Country
  • Figure 22. Global Conjugate Vaccines: by Type USD/Units (2018-2023)
  • Figure 23. Global Conjugate Vaccines share by Players 2023 (%)
  • Figure 24. Global Conjugate Vaccines share by Players (Top 3) 2023(%)
  • Figure 25. Global Conjugate Vaccines share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Bharat Biotech (India) Revenue, Net Income and Gross profit
  • Figure 28. Bharat Biotech (India) Revenue: by Geography 2023
  • Figure 29. Biological E (India) Revenue, Net Income and Gross profit
  • Figure 30. Biological E (India) Revenue: by Geography 2023
  • Figure 31. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 32. CSL Limited (Australia) Revenue: by Geography 2023
  • Figure 33. GlaxoSmithKline, plc. (United States.) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline, plc. (United States.) Revenue: by Geography 2023
  • Figure 35. Merck and Company (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck and Company (United States) Revenue: by Geography 2023
  • Figure 37. Neuron Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 38. Neuron Biotech (United States) Revenue: by Geography 2023
  • Figure 39. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 41. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 44. Sanofi Pasteur (France) Revenue: by Geography 2023
  • Figure 45. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 46. Serum Institute of India (India) Revenue: by Geography 2023
  • Figure 47. Global Conjugate Vaccines: by Type USD Million (2025-2030)
  • Figure 48. Global Conjugate Vaccines: by Patient Stage USD Million (2025-2030)
  • Figure 49. Global Conjugate Vaccines: by Pathogen USD Million (2025-2030)
  • Figure 50. Global Conjugate Vaccines: by Disease Indication USD Million (2025-2030)
  • Figure 51. South America Conjugate Vaccines Share (%), by Country
  • Figure 52. Asia Pacific Conjugate Vaccines Share (%), by Country
  • Figure 53. Europe Conjugate Vaccines Share (%), by Country
  • Figure 54. MEA Conjugate Vaccines Share (%), by Country
  • Figure 55. North America Conjugate Vaccines Share (%), by Country
  • Figure 56. Global Conjugate Vaccines: by Type K Units (2025-2030)
  • Figure 57. Global Conjugate Vaccines: by Patient Stage K Units (2025-2030)
  • Figure 58. Global Conjugate Vaccines: by Pathogen K Units (2025-2030)
  • Figure 59. Global Conjugate Vaccines: by Disease Indication K Units (2025-2030)
  • Figure 60. South America Conjugate Vaccines Share (%), by Country
  • Figure 61. Asia Pacific Conjugate Vaccines Share (%), by Country
  • Figure 62. Europe Conjugate Vaccines Share (%), by Country
  • Figure 63. MEA Conjugate Vaccines Share (%), by Country
  • Figure 64. North America Conjugate Vaccines Share (%), by Country
  • Figure 65. Global Conjugate Vaccines: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Bharat Biotech (India)
  • Biological E (India)
  • CSL Limited (Australia)
  • GlaxoSmithKline, plc. (United States.)
  • Merck and Company (United States)
  • Neuron Biotech (United States)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States)
  • Sanofi Pasteur (France)
  • Serum Institute of India (India)
Additional players considered in the study are as follows:
Pfizer (United States) , Sanofi Pasteur (France) , Others
Select User Access Type

Key Highlights of Report


Jul 2024 241 Pages 73 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Conjugate Vaccines Quantitative research analysis
Global Conjugate Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bharat Biotech (India), Biological E (India), CSL Limited (Australia), GlaxoSmithKline, plc. (United States.), Merck and Company (United States), Neuron Biotech (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States), Sanofi Pasteur (France) and Serum Institute of India (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase in Investment in Research and Development " is seen as one of major influencing trends for Conjugate Vaccines Market during projected period 2023-2030.
The Conjugate Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Conjugate Vaccines Report?

Have a Query? Click Here

Other Related Reports

Natural Killer Cells Therapeutics Comprehensive Study by Type (NK Cell Therapies, NK Cell Directed Antibodies), Application (Research Centers & Institutes, Hospitals, Others), Distribution Channel (H...
$ 3650
Mercaptopurine Comprehensive Study by Application (Leukemia, acute lymphoid Lymphoma, Non-Hodgkin’s Leukemia, Acute Myelogenous Leukemia, Chronic Myeloid), Form (Oral Suspension, Injection, Tablet, L...
$ 3650
Immunity Nutraceutical Ingredient Comprehensive Study by Type (Phytochemical and plant extracts, Omega-3 fatty acids, Minerals, Fibers & specialty carbohydrates, Carotenoids, Other Types), Applicatio...
$ 3750
Arrhythmia Monitoring Devices Comprehensive Study by Application (Hospitals & Clinics, Diagnostic Centres, Ambulatory Surgical Centers, Homecare Settings), Distribution Channel (Online Stores, Offlin...
$ 3450
Aspartame Free Gum Comprehensive Study by Type (Stick Gum, Tab Gum), Polyol Type (Erythritol, Xylitol, Others), Sales Channel (Online Sales, Offline Sales) Players and Region - Global Market Outlook ...
$ 3500
Pregnancy Care Product Comprehensive Study by Type (Stretch Mark Minimizer, Breast Cream, Toning/Firming Lotion, Itching Prevention Cream, Nipple Protection Cream, Others), Distribution Channel (Hosp...
$ 3800